Fri, March 17, 2023
Thu, March 16, 2023
Wed, March 15, 2023
Tue, March 14, 2023
Mon, March 13, 2023
Fri, March 10, 2023
Thu, March 9, 2023

Gregory Renza Reiterated (ACAD) at Buy and Held Target at $27 on, Mar 14th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -buy-and-held-target-at-27-on-mar-14th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Gregory Renza of RBC Capital, Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Buy and Held Target at $27 on, Mar 14th, 2023.

Gregory has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 4 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Uy Ear of "Mizuho" Reiterated at Hold and Held Target at $19 on, Monday, March 13th, 2023
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $20 on, Wednesday, March 1st, 2023
  • Jason West of "JMP Securities" Maintained at Hold with Decreased Target to $22 on, Tuesday, February 28th, 2023
  • Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022


This is the rating of the analyst that currently disagrees with Gregory


  • Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $22 on, Tuesday, January 3rd, 2023

Publication Contributing Sources